NCT04080661View on ClinicalTrials.gov

Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients.

PHASE4CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

March 22, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Psoriasis Vulgaris
Interventions
PROCEDURE

Venapuncture

Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of secukinumab.

OTHER

Patient questionnaires

The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.

Trial Locations (7)

3000

University Hospital Leuven, Leuven

8000

AZ Sint-Jan, Bruges

8820

AZ Delta Rembert, Torhout

9000

AZ Maria Middelares, Ghent

AZ Sint-Lucas, Ghent

University Hospital Ghent, Ghent

9990

Private practice Dermatology, Maldegem

All Listed Sponsors
collaborator

KU Leuven

OTHER

collaborator

University Ghent

OTHER

lead

University Hospital, Ghent

OTHER

NCT04080661 - Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients. | Biotech Hunter | Biotech Hunter